Michael J Stocks

List of Publications by Year in Descending Order

64 papers	1,265 citations	21 h-index	33 g-index
82 ext. papers	1,503 ext. citations	4.3 avg, IF	4.48 L-index

#	Paper	IF	Citations
64	Is Oral Lipid-Based Delivery for Drug Targeting to the Brain Feasible?. *European Journal of Pharmaceutics and Biopharmaceutics*, **2022**,	5.7	1
63	Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. *European Journal of Pharmaceutics and Biopharmaceutics*, **2021**, 162, 43-49	5.7	6
62	Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes. *International Journal of Pharmaceutics*, **2021**, 602, 120621	6.5	0
61	Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. *Journal of Controlled Release*, **2021**, 329, 1077-1089	11.7	9
60	Concurrent Reactive Oxygen Species Generation and Aneuploidy Induction Contribute to Thymoquinone Anticancer Activity. *Molecules*, **2021**, 26,	4.8	1
59	Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. *Pharmaceutics*, **2021**, 13,	6.4	3
58	Design and Evaluation of New Quinazolin-4(3)-one Derived PqsR Antagonists as Quorum Sensing Quenchers in. *ACS Infectious Diseases*, **2021**, 7, 2666-2685	5.5	5
57	Hit Identification of New Potent PqsR Antagonists as Inhibitors of Quorum Sensing in Planktonic and Biofilm Grown. *Frontiers in Chemistry*, **2020**, 8, 204	5	12
56	Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma. *Biomedical Chromatography*, **2020**, 34, e4934	1.7	3
55	Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum sensing transcriptional regulator PqsR. *European Journal of Medicinal Chemistry*, **2020**, 208, 112778	6.8	7
54	Model-Informed Drug Discovery and Development in Pulmonary Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation Evaluation of Pulmonary Suspensions. *ACS Omega*, **2020**, 5, 25733-25746	3.9	3
53	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. *ACS Medicinal Chemistry Letters*, **2020**, 11, 316-321	4.3	0
52	Modulators of CXCR4 and CXCR7/ACKR3 Function. *Molecular Pharmacology*, **2019**, 96, 737-752	4.3	30
51	Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. *Journal of Medicinal Chemistry*, **2019**, 62, 4815-4850	8.3	72
50	Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection. *Journal of Pharmaceutical Sciences*, **2019**, 108, 630-640	3.9	8
49	Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation. *Molecular Pharmaceutics*, **2018**, 15, 1578-1586	5.6	2
48	Nucleoside-Based Self-Assembling Drugs for Localized Drug Delivery. *ChemMedChem*, **2018**, 13, 1098-1101	3.7	3

47	Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y Receptor Based on AR-C118925. *Journal of Medicinal Chemistry*, **2018**, 61, 3089-3113	8.3	16
46	In Silico and in Vitro-Guided Identification of Inhibitors of Alkylquinolone-Dependent Quorum Sensing in Pseudomonas aeruginosa. *Molecules*, **2018**, 23,	4.8	28
45	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. *Journal of Controlled Release*, **2018**, 286, 10-19	11.7	26
44	Pseudomonas aeruginosa Quorum Sensing Systems as Drug Discovery Targets: Current Position and Future Perspectives. *Journal of Medicinal Chemistry*, **2018**, 61, 10385-10402	8.3	52
43	Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase [(PI3K)]Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 1534-1554	8.3	6
42	Ipratropium is 'luminally recycled' by an inter-play between apical uptake and efflux transporters in Calu-3 bronchial epithelial cell layers. *International Journal of Pharmaceutics*, **2017**, 532, 328-336	6.5	9
41	From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y receptor. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4849-4853	2.9	15
40	Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. *ACS Medicinal Chemistry Letters*, **2017**, 8, 981-986	4.3	7
39	Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development. *Journal of Medicinal Chemistry*, **2016**, 59, 9981-10005	8.3	28
38	Lead Generation Approaches Delivering Inhaled β2-Adrenoreceptor Agonist Drug Candidates. *Methods and Principles in Medicinal Chemistry*, **2016**, 575-596	0.4	
37	Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold. *ACS Medicinal Chemistry Letters*, **2015**, 6, 324-8	4.3	16
36	Linifanib--a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator. *Chemical Communications*, **2015**, 51, 6384-7	5.8	9
35	Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6891-9	3.4	35
34	Chiral Phosphoric Acid-Catalyzed Enantioselective Three- Component Aza-Diels–Alder Reactions of Aminopyrroles and Aminopyrazoles. *Advanced Synthesis and Catalysis*, **2014**, 356, 1719-1724	5.6	32
33	Preparation and structural analysis of (±)-cis-ethyl 2-sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate and (±)-trans-ethyl 2-oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylate. *Acta Crystallographica Section C, Structural Chemistry*, **2014**, 70, 1161-8	0.8	2
32	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. *ACS Medicinal Chemistry Letters*, **2014**, 5, 416-21	4.3	21
31	The small molecule drug discovery process From target selection to candidate selection **2013**, 81-126		6
30	From libraries to candidate: the discovery of new ultra long-acting dibasic β-adrenoceptor agonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 689-95	2.9	16

29	Organocatalytic enantioselective one-pot four-component ugi-type multicomponent reaction for the synthesis of epoxy-tetrahydropyrrolo[3,4-b]pyridin-5-ones. *Chemistry - A European Journal*, **2012**, 18, 12624-7	4.8	44
28	The discovery of MMP7 inhibitors exploiting a novel selectivity trigger. *ChemMedChem*, **2011**, 6, 769-73	3.7	21
27	Design driven HtL: The discovery and synthesis of new high efficacy □-agonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4027-31	2.9	19
26	Design-driven LO: the discovery of new ultra long acting dibasic □2-adrenoceptor agonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4612-6	2.9	17
25	Molybdenum-mediated synthesis of quinazolin-4(3H)-ones via cyclocarbonylation using microwave irradiation. *Tetrahedron Letters*, **2011**, 52, 3793-3796	2	31
24	Molybdenum-mediated carbonylation of aryl halides with nucleophiles using microwave irradiation. *Organic Letters*, **2010**, 12, 4280-3	6.2	93
23	The discovery of new spirocyclic muscarinic M3 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7458-61	2.9	10
22	One-Pot, Three-Component Copper-Catalysed □Click□Triazole Synthesis Utilising the Inexpensive, Shelf-Stable Diazotransfer Reagent Imidazole-1-sulfonyl Azide Hydrochloride. *Synlett*, **2009**, 2009, 1391-1394	2.2	22
21	A practical method for targeted library design balancing lead-like properties with diversity. *ChemMedChem*, **2009**, 4, 800-8	3.7	24
20	Antagonists of the P2X(7) receptor. From lead identification to drug development. *Journal of Medicinal Chemistry*, **2009**, 52, 3123-41	8.3	121
19	One-Pot Four-Component Reaction for the Generation of Pyrazoles and Pyrimidines. *Synlett*, **2008**, 2008, 100-104	2.2	39
18	Synthesis of Novel 2,6-Diazaspiro[3.3]heptanes. *Synlett*, **2007**, 2007, 2584-2586	2.2	11
17	Concise Synthesis of Novel 2,6-Diazaspiro[3.3]heptan-1-ones and Their Conversion into 2,6-Diazaspiro[3.3]heptanes. *Synlett*, **2007**, 2007, 2587-2589	2.2	7
16	Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3459-62	2.9	44
15	Efficient and regiospecific one-pot synthesis of substituted 1,2,4-triazoles. *Organic Letters*, **2004**, 6, 2969-71	6.2	69
14	A Carbonyl Ylide Approach to Substituted Furans. *Synlett*, **2001**, 2001, 0646-0648	2.2	27
13	Macrocyclic ring closures employing the Intramolecular Heck reaction. *Tetrahedron Letters*, **1995**, 36, 6555-6558	2	33
12	Synthesis of the C16-C23 Effector Domain of FK-506 via Copper-Catalysed Metallate Rearrangement of an □-Alkoxyalkenylcuprate. *Synthesis*, **1995**, 1995, 195-198	2.9	10

11	Synthesis of FK506-Cyclosporin hybrid macrocycles. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 2341-2346	2.9	2
10	Synthetic FKBP12 ligands. Design and synthesis of pyranose replacements.. *Bioorganic and Medicinal Chemistry Letters*, **1994**, 4, 2501-2506	2.9	6
9	Synthesis and evaluation of dual domain macrocyclic FKBP12 ligands.. *Bioorganic and Medicinal Chemistry Letters*, **1994**, 4, 2507-2510	2.9	7
8	The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506. *Bioorganic and Medicinal Chemistry Letters*, **1994**, 4, 1457-1460	2.9	5
7	The affinity of the excised binding domain of FK-506 for the immunophilin FKBP12.. *Bioorganic and Medicinal Chemistry Letters*, **1993**, 3, 1947-1950	2.9	13
6	A novel rearrangement reaction conversion of 3-(chloromethyl)azetidin-2-ones to azetidine-3-carboxylic acid esters. *Tetrahedron Letters*, **1991**, 32, 4795-4798	2	8
5	Intramolecular cyclisation-N-dealkylation of azetidine-3-acetic acids. *Tetrahedron Letters*, **1991**, 32, 4799-4800	2	7
4	A synthesis of the C16-C23 segment of FK-506. *Tetrahedron Letters*, **1990**, 31, 1637-1640	2	18
3	Recent Progress in Research on the Immunosuppressant FK-506 **1990**, 131-165		
2	A Synthesis of the C24-C34 Segment of FK 506. *Synlett*, **1990**, 1990, 38-39	2.2	22
1	A synthesis of the C(1)-C(15) segment of tsukubaenolide (FK 506).. *Tetrahedron Letters*, **1988**, 29, 4481-4484	2	41